Company intelligence / Profile preview

Propella Therapeutics

Ownership: Private
Development stage: Phase 1

Overview

Propella Therapeutics developed a proprietary lymphatic targeting platform to enhance delivery of small molecule drugs for oncology and pain. Its lead candidate, PRL‑02, an androgen biosynthesis inhibitor for prostate cancer, reached the clinical stage before the company was acquired by Astellas Pharma in December 2023. Other pipeline assets include a TRPV1 agonist for pain and a preclinical herpes simplex therapy.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

abiraterone decanoate

Phase 1

Indications: Prostate cancer, Metastatic castration-resistant prostate cancer, Metastatic castration-sensitive prostate cancer

Partnerships

Acquired by Astellas Pharma Inc.; no other major partnerships disclosed publicly at time of acquisition.

Beyond the preview

Go deeper on Propella Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Propella Therapeutics.

Explore the full profile